Preventing kidney disease progression in type 1 diabetes with a new drug
Treatments studied
Part of Hormones & metabolism, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether a daily medication can slow down kidney damage in people with type 1 diabetes who already have some kidney problems. It may help protect your kidneys from getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have type 1 diabetes.
- Your kidneys show signs of damage (protein in your urine) and your kidney function is mildly to moderately reduced.
- You are already taking a blood pressure medication that protects the kidneys (like an ACE inhibitor or ARB).
- You have not had diabetic ketoacidosis (except at diagnosis) and your blood sugar is not severely uncontrolled.
- You are not pregnant, breastfeeding, or planning to become pregnant in the next year.
- You have not taken an SGLT2 inhibitor (like empagliflozin or dapagliflozin) in the last 8 weeks, and you are not allergic to them.
- You do not have severe heart failure, recent heart attack or stroke, or frequent urinary/genital infections.
- You are able to undergo MRI scans (no metal implants, no claustrophobia, no recent surgery).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether sotagliflozin (a pill that helps control blood sugar and protects the kidneys) can slow down kidney function decline in people with type 1 diabetes and diabetic kidney disease. You may qualify if you have had type 1 diabetes for at least 8 years, have moderate kidney damage, and are on standard treatments.
This trial tests a medication called dapagliflozin (often used in type 2 diabetes) to see if it can help protect the kidneys in people with type 1 diabetes who already have some signs of kidney damage. If it works, it could slow down further kidney decline.
This study tests new treatments for people with long-standing type 1 diabetes who also have early signs of heart or kidney disease. The goal is to see if these treatments can help protect the heart and kidneys.
This study tests whether using a dual continuous glucose and ketone monitor can help people with type 1 diabetes safely take a class of drugs called SGLT2 inhibitors, which may improve blood sugar control but can increase the risk of diabetic ketoacidosis (DKA). By closely monitoring changes in glucose and ketone levels, the study aims to prevent dangerous episodes while benefiting from the drug's effects.
This trial tests whether a medicine called ganagliflozin can slow down kidney damage in people with type 2 diabetes and chronic kidney disease. If you qualify, you may be able to take part in this study to see if it helps protect your kidneys.
This Phase 2 study compares tofogliflozin to metformin to see how well they reduce urine albumin levels (a marker of kidney stress) in people with diabetic kidney disease. You might benefit if your type 2 diabetes is affecting your kidneys despite standard blood-pressure medicines.
Hear when a new Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.